<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121019">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01911871</url>
  </required_header>
  <id_info>
    <org_study_id>NI10071</org_study_id>
    <secondary_id>RAF11005</secondary_id>
    <nct_id>NCT01911871</nct_id>
  </id_info>
  <brief_title>Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations</brief_title>
  <acronym>SUFEMYO</acronym>
  <official_title>Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' primary objective is to study prevalences of myocardial iron overload,
      defined as a cardiac T2*&lt; 20 ms, in 3 populations of multiply transfused patients, affected
      with thalassemia, sickle cell disease, and myelodysplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The inevestigators' primary objective is to study prevalences of myocardial iron overload,
      defined as a cardiac T2*&lt; 20 ms, in 3 populations of multiply transfused patients, affected
      with thalassemia, sickle cell disease, and myelodysplasia.

      The investigators will record concomitantly parameters which, according to literature data,
      may influence the occurrence of this complication, and will look for correlations with these
      parameters and iron overload (secondary objectives), in each of the 3 cohorts.

      14 centres are involved and enrol patients with thalassemia, or sickle cell disease, or
      myelodysplasia having received in the past year &gt; 8 erythrocyte concentrates, and having had
      a cardiac MRI. Patients files register the type of the disease, age at the beginning of
      transfusion and chelation, chelator type and dosage, liver and cardiac T2*.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Cardiac T2* (MRI)</measure>
    <time_frame>Day 0</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver T2*(MRI)</measure>
    <time_frame>Day 0</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Thalassemia</condition>
  <condition>Sickle Cell Disease</condition>
  <condition>Myelodysplasia</condition>
  <arm_group>
    <arm_group_label>thalassemia</arm_group_label>
    <description>patients affected with thalassemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sickle cell disease</arm_group_label>
    <description>patients affected with sickle cell disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>myelodysplasia</arm_group_label>
    <description>patients affected with myelodysplasia</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>a blood sample was taken on the day of inclusion</description>
    <arm_group_label>thalassemia</arm_group_label>
    <arm_group_label>sickle cell disease</arm_group_label>
    <arm_group_label>myelodysplasia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients affected with thalassemia, SCD, and myelodysplasia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Thalassemia, sickle cell disease, myelodysplasia

          -  having received in the past year &gt; 8 erythrocyte concentrates

          -  &gt; 6 years of age

        Exclusion Criteria:

          -  preexisting cardiac disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariane de montalembert, MD/PhD</last_name>
    <role>Study Director</role>
    <affiliation>Groupement Hospitalier Necker</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariane de Montalembert, MD/PHD</last_name>
    <phone>00 33 1 44 49 48 96</phone>
    <email>mariane.demontal@nck.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurence Lecomte, PhD</last_name>
    <phone>00 33 1 58 41 35 45</phone>
    <email>laurence.lecomte@nck.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariane de Montalembert, MD/PHD</last_name>
      <phone>00 33 1 44 49 48 96</phone>
      <email>mariane.demontal@nck.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Laurence Lecomte, PhD</last_name>
      <phone>00 33 1 58 41 35 45</phone>
      <email>laurence.lecomte@cch.aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 29, 2013</lastchanged_date>
  <firstreceived_date>July 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thalassemia</keyword>
  <keyword>sickle cell disease</keyword>
  <keyword>myelodysplasia</keyword>
  <keyword>transfusion</keyword>
  <keyword>chelation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
